New York City (18 June 2020) —  Jumo Health,  a global provider of age appropriate, personalized health care resources, is pleased to announce the appointment of Brandon Cormier to the Company’s Board of Directors. Mr. Cormier, currently the Chief Commercial Officer at Elligo Health Research, joins the Company to expand its expertise within the clinical trial sector where they serve both pediatric and adult cohorts.

“As we continue to invest in the clinical trials sector, the addition of Brandon strengthens our Board by providing valuable market intelligence and guidance during this critical period of growth,” shared Kevin Aniskovich, President and CEO of Jumo Health. “Brandon’s operational and sales experience is a natural extension of the expertise held among our current Directors and advisors,” concluded Aniskovich.

Mr. Cormier joins the Jumo Health Board of Directors with over 20 years of extensive experience in the pharmaceutical and CRO sectors.  In addition to his current role at Elligo Health Research, he has held various leadership roles within sales and clinical development within leading organizations such as Syneos Health, INC Research, and GlaxoSmithKline. In addition, Mr. Cormier was  a member of the Board of Directors for Syneos Health Canada.

“Jumo Health has made significant progress addressing the unmet need of age appropriate educational resources for patients and their care circle for use along the entire patient journey. I am delighted to join Jumo Health’s Board of Directors and excited to contribute to the continued growth and success of the Company,” stated Mr. Cormier.

To learn more about Jumo Health, visit JumoHealth.com.